Manuscript no. HAEMATOL037978 entitled "Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy"

Authors: Mark van Duin, Annemiek Broyl, Yvonne de Knegt, Hartmut Goldschmidt, Paul G. Richardson, Wim C. J. Hop, Bronno van der Holt, Debora Joseph Pietras, George Mulligan, Rachel Neuwirth, Surinder S. Sahota and Pieter Sonneveld

Information about the contributions of each person named as having participated in the study

Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
Mark van Duin, Erasmus MC, m.vanduin@erasmusmc.nl

According to the International Committee of Medical Journal Editors (ICMJE) (<u>http://www.icmje.org/ethical_1author.html</u>): "Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 <u>Acquisition of funding, collection of data, or general supervision of the</u> <u>research group alone does not constitute authorship</u>".

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the **conception of the study**: Mark van Duin, Erasmus MC, m.vanduin@erasmusmc.nl, Surinder Sahota, University of Southampton School of Medicine, <u>s.s.sahota@soton.ac.uk</u>, Pieter Sonneveld, Erasmus MC, p.sonneveld@erasmusmc.nl

3) **Design & Methods**. The following authors were responsible for specific investigations (please detail):

• Mark van Duin was responsible for collating all data and carrying out all final analyses concerning both newly diagnosed (HOVON65/GMMG-HD4) and relapsed patients (APEX/SUMMIT/CREST)

• Annemiek Broyl and Yvonne de Knegt were responsible for gene expression data acquisition and analysis of the HOVON65/GMMG-HD4 dataset

• Hartmut Goldschmidt was responsible for clinical analysis of the German section of the HOVON65/GMMG-HD4 study

- Paul Richardson was responsible for clinical data acquisition of the APEX/SUMMIT/CREST trials
- Wim Hop was responsible for statistical analysis

• Bronno van der Holt was responsible for clinical data acquisition of the HOVON65/GMMG-HD4 study and statistical analysis

- Debora Joseph Pietras was responsible for data acquisition and practical assistance
- George Mulligan and Rachel Neuwirth were responsible for gene expression data acquisition and analysis of the APEX/SUMMIT/CREST trials

4) **Results**. The following authors were responsible for specific portions of the results, including figures and tables (please indicate the person responsible for each figure and each table):

• Mark van Duin was responsible for Table 1 and Figure 1 as well as for the supplemental data.

• As indicated, Wim Hop and Bronno van der Holt were responsible for the statistics as shown in Table 1 and Figure 1.

5) Writing the manuscript. The following authors were responsible for writing the manuscript:

- Mark van Duin was responsible for the outline and all writing of the manuscript
- Surinder Sahota was responsible for critical revision and initial drafts

• Pieter Sonneveld and Annemiek Broyl were responsible for critical revision.

• Yvonne de Knegt, Hartmut Goldschmidt, Paul Richardson, Wim Hop, Bronno van der Holt, Debora Joseph Pietras, George Mulligan and Rachel Neuwirth were responsible for overall revision

6) Contributors Listed in Acknowledgments:

Hans Stoop was responsible for excellent technical assistance. The Leukemia Research Foundation (UK) and the Myeloma Stem Cell Network (MSCNET/FP6) contributed funding to this study.